Juan Andres - 09 Feb 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
09 Feb 2022
Net transactions value
-$402,109
Form type
4
Filing time
11 Feb 2022, 15:53:38 UTC
Previous filing
04 Feb 2022
Next filing
18 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $28,440 +2,000 $14.22* 2,000 09 Feb 2022 Direct F1
transaction MRNA Common Stock Sale $308,520 -2,000 -100% $154.26 0 09 Feb 2022 Direct F1
transaction MRNA Common Stock Options Exercise $0 +1,740 $0.000000 1,740 09 Feb 2022 Direct F2
transaction MRNA Common Stock Sale $122,029 -768 -44% $158.89 972 10 Feb 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -2,000 -7.5% $0.000000 24,629 09 Feb 2022 Common Stock 2,000 $14.22 Direct F1, F4
transaction MRNA Restricted Stock Units Options Exercise $0 -1,740 -25% $0.000000 5,223 09 Feb 2022 Common Stock 1,740 $0.000000 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F4 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.
F5 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer